After meeting with the FDA, biopharmaceuticals company Alterity Therapeutics (ASX: ATH) has confirmed Phase II clinical trial plans for their ATH434 compound in the treatment of Multiple System Atrophy (MSA), an incurable Parkinsonian disorder with no regulatory precedent. Due to the unique scenario where there are no accepted efficacy endpoints, guidance has been provided by
Read More
Following preliminary eco-toxicity studies on limited aquatic species, agtech developer Bio-Gene Technology (ASX: BGT) has reported favourable results for its flagship next-gen insecticide, Flavocide. The studies were completed on guppy fish, water fleas and freshwater algae which represented key species of marine life most likely to be impacted by the introduction of pesticide. Following application
Read More
3D printing medtech company Osteopore (ASX: OSX) is set to continue their successful streak, following news that the company has received Australian Therapeutics Goods Administration (TGA) approval for three craniofacial products, after being placed into a trading halt Friday afternoon. The Osteomesh, Osteoplug, and Osteoplug-C, are used primarily to fill voids in a patient’s bone,
Read More
Biotech company Genetic Signatures (ASX: GSS) is poised to play a major role in flattening the curve of coronavirus cases in Australia after the Therapeutics Goods Association (TGA) approved their SARS-CoV-2 Detection Kit for sale in Australia. Regulatory approval in Australia follows authorisation which was granted in Europe 10 days ago with Genetic Signatures able
Read More
Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. The granting of the new patent is the third jurisdiction to do so for Neuren with the same application
Read More
Carried and administered by Australian paramedics for decades, the green whistle pain reliever has been on the Australian market for years but clinical trials in Europe have now revealed Penthrox® to be a superior pain relief product than traditional treatments of morphine (IV), paracetamol, ketoprofen and NSAIDS. Marketed as Penthrox® with the key ingredient of
Read More